ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference
Leerink Global Healthcare Conference 2014
WOBURN, Mass. -- February 5, 2014
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at
the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014
at 8:25 a.m. The presentation will be web cast and may be accessed through the
investor relations section of the Company’s website, http://www.arqule.com.
ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase and ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s
current discovery efforts, which are based on the ArQule Kinase Inhibitor
Platform (AKIP™), are focused on the identification of novel kinase inhibitors
that are potent and selective against their targets.
William B. Boni, 781-994-0300
VP, Investor Relations/
Press spacebar to pause and continue. Press esc to stop.